The initial success of the copyright undeniably reshaped the pharmaceutical landscape, but placing funds in companies primarily reliant on unbranded versions presents a complex picture. While early earnings were impressive, the cessation of patents and the appearance of discounted alternatives have eroded market share. Thus, a thorough assessmen… Read More